Brought to you by 
Series C brings in $60mm for Dicerna
31 Jan 2014
Executive Summary
RNAi therapeutics developer Dicerna Pharmaceuticals Inc. brought in $60mm through an oversubscribed Series C financing led by first-time backer RA Capital, which adds a board member and was joined by other new investors Brookside Capital, Deerfield, and Omega Funds, and returning shareholders Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures, and SR One. Funds will be used to advance two or more programs into clinical trials (expected in early 2014) and for ongoing work on preclinical candidates.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C brings in $60mm for Dicerna
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice